About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis

By: via Business Wire

NM26 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets, targeting the underlying inflammation as well as the neuroinflammatory pathway that causes itch

MAD data expected to be reported in mid-2024; Single ascending dose (SAD) cohort in healthy volunteers remains ongoing

Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the first patient has been dosed in the multiple ascending dose (MAD) study of the Phase 1a/b clinical trial of NM26, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD).

The MAD study in AD patients is a planned continuation of the Company’s ongoing single ascending dose (SAD) portion of the Phase 1a/b trial in healthy volunteers. NM26 is designed to simultaneously block itch and inflammation by inhibiting the three key cytokine-signaling pathways involved in disease pathogenesis of AD: IL-4, IL-13, and IL-31, the latter specifically targeting the neuroinflammatory pathway that causes itch.

“Dosing the first patient with NM26 represents a major milestone for Numab as we advance development of NM26 in atopic dermatitis and potentially other inflammatory and immune-mediated diseases,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics. “We believe that NM26 has the potential to deliver faster relief from itch and more pronounced improvement of skin lesions than the current standard of care and therefore provide a more effective therapeutic option for patients. We look forward to evaluating the potential of NM26 and expect to report preliminary data from the MAD part of the study in mid-2024.”

AD is an inflammatory skin condition which is characterized by a vicious cycle of skin inflammation that causes itching and scratching, the latter in turn exacerbates damage to the skin barrier and inflammation and furthers itching, resulting in the characteristic skin lesions for which AD is known. In the United States and the European Union markets, approximately 17-26 million patients suffer from moderate-to-severe AD.

The Phase 1a/1b trial is a randomized, double-blind, placebo-controlled study of subcutaneous (SC) administration of NM26 in healthy volunteers and adult patients with moderate-to-severe AD to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple ascending doses of NM26 as well as exploratory clinical activity in the MAD part of the trial. The trial is being conducted in collaboration with Asia-regional partner Kaken Pharmaceutical. For additional information on this trial (NCT05859724), please visit www.clinicaltrials.gov.

About NM26 (NM26-2198)

NM26 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis (AD). The antibody therapeutic is designed to prevent IL- 4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis. Addition of IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade is expected to enable a faster onset of action and demonstrate superior efficacy over current and emerging standard of care in AD, together with convenient subcutaneous administration. Numab is developing this molecule together with its regional partner Kaken Pharmaceutical, which owns commercial rights to certain Asian territories, including Japan.

About Numab Therapeutics

Numab Therapeutics is an immunology and oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in addressing unmet needs in inflammatory diseases and cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform, we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit www.numab.com.

About Kaken Pharmaceutical

Kaken is an R&D driven pharmaceutical company, established in 1948, and its corporate philosophy is to help improve the quality of life of patients by serving as many people as possible to return smiles of happiness to their faces, through supplying superior pharmaceuticals. Recently, Kaken has increased its presence in dermatology and orthopedics, and Clenafin, a drug discovered in-house and first topical onychomycosis treatment in Japan, continues to grow as a global product. For more information, please visit https://www.kaken.co.jp/english/.

Contacts

More News

View More
Carmax: Now is the Time to Load Up On This Used Car Stock
Via MarketBeat
Topics Economy World Trade
Tickers KMX
Why Affirm Could Be the Next Big Winner in Rate-Cut Rally
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers AFRM
Sprouts, Darden Offer High-Upside Setups for Risk-Takers
Via MarketBeat
Tickers DRI SFM
Jabils AI-Driven Boom Has Begun: News Highs are Coming
Via MarketBeat
Topics Artificial Intelligence
Tickers AAPL AMZN JBL JNJ
NuScale, Rocket Lab Face Heavy Insider Selling After Surges
Via MarketBeat
Tickers FLR RKLB SMR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.